WO1999048499A1 - Paroxetine compositions - Google Patents

Paroxetine compositions Download PDF

Info

Publication number
WO1999048499A1
WO1999048499A1 PCT/GB1999/000922 GB9900922W WO9948499A1 WO 1999048499 A1 WO1999048499 A1 WO 1999048499A1 GB 9900922 W GB9900922 W GB 9900922W WO 9948499 A1 WO9948499 A1 WO 9948499A1
Authority
WO
WIPO (PCT)
Prior art keywords
paroxetine
solvent
pharmaceutically acceptable
adsorbed
acceptable derivative
Prior art date
Application number
PCT/GB1999/000922
Other languages
French (fr)
Inventor
Andrew Simon Craig
Neal Ward
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EA200000977A priority Critical patent/EA003393B1/en
Priority to IL13847899A priority patent/IL138478A0/en
Priority to JP2000537547A priority patent/JP2002507569A/en
Priority to CA002324612A priority patent/CA2324612A1/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Priority to KR1020007010550A priority patent/KR20010042145A/en
Priority to PL99343095A priority patent/PL343095A1/en
Priority to APAP/P/2000/001914A priority patent/AP2000001914A0/en
Priority to NZ506893A priority patent/NZ506893A/en
Priority to BR9908991-2A priority patent/BR9908991A/en
Priority to AU30451/99A priority patent/AU754765B2/en
Priority to EP99911940A priority patent/EP1063993A1/en
Priority to SK1410-2000A priority patent/SK14102000A3/en
Publication of WO1999048499A1 publication Critical patent/WO1999048499A1/en
Priority to NO20004740A priority patent/NO313404B1/en
Priority to BG104865A priority patent/BG104865A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Definitions

  • PAROXETINE COMPOSITIONS The present invention relates to new formulations of a pharmaceutically active compound, and in particular to a novel formulation of paroxetine.
  • this compound is usually isolated as an acid salt, especially the hydrochloride.
  • Paroxetine is approved for human use as the hydrochloride salt, and has been proposed for the treatment and prophylaxis of inter alia depression, obsessive compulsive disorder (OCD) and panic.
  • Paroxetine hydrochloride has been described in the literature as a crystalline hemihydrate (see EP-A-0223403 of Beecham Group) and as various crystalline anhydrate forms (see WO96/24595 of SmithKline Beecham).
  • Paroxetine free base has hitherto been disclosed in the literature as an oil, and so the free base has not itself been considered for therapeutic use, preference being given to crystalline forms which can be more easily purified and processes into dosage forms.
  • paroxetine for example paroxetine free base
  • paroxetine free base is advantageously formulated into pharmaceutical compositions when adsorbed on or absorbed by a solid carrier.
  • the present invention provides a composition comprising paroxetine or a pharmaceutically acceptable derivative thereof adsorbed on or absorbed by a pharmaceutically acceptable solid carrier, and the use of the composition as a therapeutic agent or for the manufacture of a medicament.
  • paroxetine may be obtained as a free-flowing powder that can be used directly (for example by direct compression into tablet form) or with further compounding ingredients in therapy.
  • paroxetine used in carrying out this invention is preferably paroxetine free base, but may alternatively be a pharmaceutically acceptable derivative such as a salt, more especially the hydrochloride.
  • composition of this invention is simply obtained by combining a solution of paroxetine with a suitable adsorbent or absorbent material and evaporating the solvent, for example by spray drying.
  • the solvent is suitably toluene, ethanol, acetone, propan-2-ol, or ethyl acetate, or any other suitable solvent or mixture of solvents, in a paroxetine concentration of between 1 and 20%, more preferably between 1 and 4%.
  • an oil obtained by removal of solvent from a solution may be blended with a solid adsorbent or absorbent material.
  • the material selected as carrier for the paroxetine is an excipient suitable for tablet formation or as a fill material for gelatine capsules, such as cyclodextrin (beta and /or gamma), porous silicates, starch, lactose or calcium phosphate, silica, sorbitol, maltodextrin, microcrystalline or powdered cellulose, sodium or calcium carboxymethylcellulose, calcium carbonate, kaolin, magnesium aluminium silicate. Additionally, soluble excipients such as magnesium stearate may form part of the solution phase.
  • the carrier is one that also has a taste-masking effect, for example ion- exchange resins.
  • a solution of paroxetine free base may be prepared by addition of a base such as triethylamine to a solution of a crystalline paroxetine salt especially the hydrochloride or acetate.
  • the solution may be prepared by basifying a solution of an amorphous paroxetine hydrochloride or a crystalline anhydrate or hydrated form of paroxetine hydrochloride.
  • paroxetine free base may be prepared as a solution or oil by adding a base such as potassium hydroxide to a solution of a N-protected paroxetine compound such as N-phenoxycarbonyl paroxetine.
  • composition of this invention comprising paroxetine adsorbed on or absorbed by a solid carrier may be formulated with or without conventional excipients for tablet formation or used as a powder fill for capsules.
  • the amount of paroxetine used is adjusted such that in a single unit dose there is a therapeutically effective amount of paroxetine.
  • the unit dose contains from 10 to 100 mg paroxetine (as measured in terms of the free base). More preferable the amount of paroxetine in a unit dose is lOmg, 20mg, 30mg, 40mg or 50mg. The most preferred amount of paroxetine in a unit dose is 20mg.
  • paroxetine product of this invention includes treatment of: alcoholism, anxiety, depression, obsessive compulsive disorder, panic disorder, chronic pain, obesity, senile dementia, migraine, bulimia, anorexia, social phobia, pre-menstrual syndrome (PMS), adolescent depression, trichotillomania, dysthymia, and substance abuse, referred to below as "the disorders”.
  • the disorders include treatment of: alcoholism, anxiety, depression, obsessive compulsive disorder, panic disorder, chronic pain, obesity, senile dementia, migraine, bulimia, anorexia, social phobia, pre-menstrual syndrome (PMS), adolescent depression, trichotillomania, dysthymia, and substance abuse, referred to below as "the disorders”.
  • the present invention also provides:
  • a pharmaceutical composition for treatment or prophylaxis of the disorders comprising paroxetine or a pharmaceutically acceptable derivative thereof adsorbed on or absorbed by a solid carrier and, optionally, at least one further pharmaceutically acceptable excipient; the use of paroxetine or a pharmaceutically acceptable derivative thereof adsorbed on or absorbed by a solid carrier to manufacture a medicament for the treatment or prophylaxis of the disorders; and
  • a method of treating the disorders which comprises administering an effective or prophylactic amount of paroxetine or a pharmaceutically acceptable derivative thereof adsorbed on or absorbed by a solid carrier to a person suffering from one or more of the disorders.
  • Example 1 Preparation of tablet pre-mix containing paroxetine free base.
  • a mixture of dibasic calcium phosphate dihydrate (408 g), hydroxypropylmethyl cellulose (25 g) and sodium starch glycollate (25 g) was blended in a key granulator for 3 minutes at a stir rate of 240 r.p.m. and an impeller rate of 3000 r.p.m.
  • Purified water (57 ml) was added at a rate of approximately 4 ml/minute for 13.5 minutes while the key granulator was set at a stir rate of 240 r.p.m. and the impeller rate was set at 1500 r.p.m.
  • the mixture was stirred for a further 1 minute, and the resulting granules dried in an air oven at 50°C for 3 hours.
  • This product is suitable for direct compression into tablets containing 10, 20, or 30 mg paroxetine.
  • N-phenoxycarbonyl paroxetine 50.0g
  • potassium hydroxide 45.0g
  • toluene 750ml
  • distilled water 500ml
  • the organic layer was separated, dried over magnesium sulfate and concentrated to a total volume of 85ml.
  • Toluene (100ml) was added to an aliquot of the solution of paroxetine free amine in toluene ( 0.43g/ml) ( 2.4 ml) and to this solution was added Celite ( 25. Og ) and the mixture stirred for 5 minutes. Solvent was removed under reduced pressure (water bath 55°C) to afford the Celite supported paroxetine free amine as a free moving powdery solid (26. Og).
  • This product may be mixed with additional excipients and compressed into tablets or added directly to capsule shells to make a product containing a therapeutic dose of paroxetine.
  • Example 3 Spray drying of paroxetine hydrochloride solution onto a suspended carrier material.
  • Anhydrous paroxetine hydrochloride 60 g was dissolved in anhydrous ethanol (725 ml) and the clear solution slurried with maltodextrin DE4-6 (506 g).
  • the uniform suspension was spray-dried in a Niro Mobile Minor (TM) closed cycle spray dryer using nitrogen as the process gas, a rotary atomiser wheel spinning at 27,000 r.p.m. (alternatively a co- current or fountain two-fluid nozzle could be used), an inlet temperature of 96-104 C and outlet temperature of 44-50 C at a feed rate of 4.1 kg per hour.
  • a white free-flowing product was recovered (490 g) which was found to have a mean particle size of 84 microns.
  • a mixture of dibasic calcium phosphate dihydrate (408 g), hydroxypropylmethyl cellulose (25 g) and sodium starch glycollate (25 g) was blended in a key granulator for 3 minutes at a stir rate of 240 r.p.m. and an impeller rate of 3000 r.p.m.
  • Purified water (57 ml) was added at a rate of approximately 4ml/minute for 13.5 minutes while the key granulator was set at a stir rate of 240 r.p.m. and the impeller rate was set at 1500 r.p.m.
  • the mixture was stirred for a further 1 minute, and the resulting granules dried in an air oven at 50°C for 3 hours.
  • N-phenoxycarbonyl paroxetine 50.0 g
  • potassium hydroxide 45.0 g
  • toluene 750 ml
  • distilled water 500 ml
  • Tablet granules ( 25. Og ), prepared as in Example 4, were added and the mixture stirred at 60°C for 5 minutes. Solvent was removed under reduced pressure at 60°C for 5 minutes.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Paroxetine is adsorbed on a carrier to form a free-flowing powder useful for capsule filling or for tablet formation; and used in therapy to treat depression.

Description

PAROXETINE COMPOSITIONS The present invention relates to new formulations of a pharmaceutically active compound, and in particular to a novel formulation of paroxetine.
Pharmaceutical products with antidepressant and anti-Parkinson properties are described in US-A-3912743 and US-A-4007196. An especially important compound among those disclosed is paroxetine, the (-)trans isomer of 4-(4'-fluorophenyl)-3-(3',4'- methylenedioxy-phenoxymethyl)-piperidine.
In the literature this compound is usually isolated as an acid salt, especially the hydrochloride. Paroxetine is approved for human use as the hydrochloride salt, and has been proposed for the treatment and prophylaxis of inter alia depression, obsessive compulsive disorder (OCD) and panic.
Paroxetine hydrochloride has been described in the literature as a crystalline hemihydrate (see EP-A-0223403 of Beecham Group) and as various crystalline anhydrate forms (see WO96/24595 of SmithKline Beecham).
Paroxetine free base has hitherto been disclosed in the literature as an oil, and so the free base has not itself been considered for therapeutic use, preference being given to crystalline forms which can be more easily purified and processes into dosage forms.
The present invention is based on the discovery that paroxetine, for example paroxetine free base, is advantageously formulated into pharmaceutical compositions when adsorbed on or absorbed by a solid carrier.
The present invention provides a composition comprising paroxetine or a pharmaceutically acceptable derivative thereof adsorbed on or absorbed by a pharmaceutically acceptable solid carrier, and the use of the composition as a therapeutic agent or for the manufacture of a medicament. By this invention paroxetine may be obtained as a free-flowing powder that can be used directly (for example by direct compression into tablet form) or with further compounding ingredients in therapy.
The paroxetine used in carrying out this invention is preferably paroxetine free base, but may alternatively be a pharmaceutically acceptable derivative such as a salt, more especially the hydrochloride.
The composition of this invention is simply obtained by combining a solution of paroxetine with a suitable adsorbent or absorbent material and evaporating the solvent, for example by spray drying. The solvent is suitably toluene, ethanol, acetone, propan-2-ol, or ethyl acetate, or any other suitable solvent or mixture of solvents, in a paroxetine concentration of between 1 and 20%, more preferably between 1 and 4%.
Alternatively an oil obtained by removal of solvent from a solution may be blended with a solid adsorbent or absorbent material.
Typically the material selected as carrier for the paroxetine is an excipient suitable for tablet formation or as a fill material for gelatine capsules, such as cyclodextrin (beta and /or gamma), porous silicates, starch, lactose or calcium phosphate, silica, sorbitol, maltodextrin, microcrystalline or powdered cellulose, sodium or calcium carboxymethylcellulose, calcium carbonate, kaolin, magnesium aluminium silicate. Additionally, soluble excipients such as magnesium stearate may form part of the solution phase.
Advantageously the carrier is one that also has a taste-masking effect, for example ion- exchange resins.
A solution of paroxetine free base may be prepared by addition of a base such as triethylamine to a solution of a crystalline paroxetine salt especially the hydrochloride or acetate. Alternatively the solution may be prepared by basifying a solution of an amorphous paroxetine hydrochloride or a crystalline anhydrate or hydrated form of paroxetine hydrochloride.
The preparation of the free base and the maleic acid salt are described in Example 2 of US 4007196. The acetate salt may also be used as a starting material. Procedures for forming salts are described in EP-A-0223403.
Additionally the paroxetine free base may be prepared as a solution or oil by adding a base such as potassium hydroxide to a solution of a N-protected paroxetine compound such as N-phenoxycarbonyl paroxetine.
The composition of this invention comprising paroxetine adsorbed on or absorbed by a solid carrier may be formulated with or without conventional excipients for tablet formation or used as a powder fill for capsules.
The amount of paroxetine used is adjusted such that in a single unit dose there is a therapeutically effective amount of paroxetine. Preferably the unit dose contains from 10 to 100 mg paroxetine (as measured in terms of the free base). More preferable the amount of paroxetine in a unit dose is lOmg, 20mg, 30mg, 40mg or 50mg. The most preferred amount of paroxetine in a unit dose is 20mg.
Therapeutic uses of the paroxetine product of this invention include treatment of: alcoholism, anxiety, depression, obsessive compulsive disorder, panic disorder, chronic pain, obesity, senile dementia, migraine, bulimia, anorexia, social phobia, pre-menstrual syndrome (PMS), adolescent depression, trichotillomania, dysthymia, and substance abuse, referred to below as "the disorders".
Accordingly, the present invention also provides:
a pharmaceutical composition for treatment or prophylaxis of the disorders comprising paroxetine or a pharmaceutically acceptable derivative thereof adsorbed on or absorbed by a solid carrier and, optionally, at least one further pharmaceutically acceptable excipient; the use of paroxetine or a pharmaceutically acceptable derivative thereof adsorbed on or absorbed by a solid carrier to manufacture a medicament for the treatment or prophylaxis of the disorders; and
a method of treating the disorders which comprises administering an effective or prophylactic amount of paroxetine or a pharmaceutically acceptable derivative thereof adsorbed on or absorbed by a solid carrier to a person suffering from one or more of the disorders.
The invention is illustrated by the following Examples:
Example 1. Preparation of tablet pre-mix containing paroxetine free base.
A mixture of dibasic calcium phosphate dihydrate (408 g), hydroxypropylmethyl cellulose (25 g) and sodium starch glycollate (25 g) was blended in a key granulator for 3 minutes at a stir rate of 240 r.p.m. and an impeller rate of 3000 r.p.m. Purified water (57 ml) was added at a rate of approximately 4 ml/minute for 13.5 minutes while the key granulator was set at a stir rate of 240 r.p.m. and the impeller rate was set at 1500 r.p.m. The mixture was stirred for a further 1 minute, and the resulting granules dried in an air oven at 50°C for 3 hours.
A portion of the granules prepared above (50 g) was added to a solution of paroxetine free base (2.0 g) in propan-2-ol (50 ml) and the resulting slurry dried under vacuum with agitation at 50°C.
This product is suitable for direct compression into tablets containing 10, 20, or 30 mg paroxetine.
Example 2. Preparation of a solid supported form of paroxetine free base.
A stirred mixture of N-phenoxycarbonyl paroxetine ( 50.0g ), potassium hydroxide (45.0g) and toluene ( 750ml) was heated to reflux under a nitrogen atmosphere for 3 hours. After allowing the mixture to cool to room temperature, distilled water (500ml) was added and the mixture stirred for 30 minutes. The organic layer was separated, dried over magnesium sulfate and concentrated to a total volume of 85ml.
Toluene (100ml) was added to an aliquot of the solution of paroxetine free amine in toluene ( 0.43g/ml) ( 2.4 ml) and to this solution was added Celite ( 25. Og ) and the mixture stirred for 5 minutes. Solvent was removed under reduced pressure (water bath 55°C) to afford the Celite supported paroxetine free amine as a free moving powdery solid (26. Og).
This product may be mixed with additional excipients and compressed into tablets or added directly to capsule shells to make a product containing a therapeutic dose of paroxetine.
Example 3 Spray drying of paroxetine hydrochloride solution onto a suspended carrier material.
Anhydrous paroxetine hydrochloride (60 g) was dissolved in anhydrous ethanol (725 ml) and the clear solution slurried with maltodextrin DE4-6 (506 g). The uniform suspension was spray-dried in a Niro Mobile Minor (TM) closed cycle spray dryer using nitrogen as the process gas, a rotary atomiser wheel spinning at 27,000 r.p.m. (alternatively a co- current or fountain two-fluid nozzle could be used), an inlet temperature of 96-104 C and outlet temperature of 44-50 C at a feed rate of 4.1 kg per hour. A white free-flowing product was recovered (490 g) which was found to have a mean particle size of 84 microns.
Example 4
Preparation of tablet pre-mix containing paroxetine hydrochloride.
A mixture of dibasic calcium phosphate dihydrate (408 g), hydroxypropylmethyl cellulose (25 g) and sodium starch glycollate (25 g) was blended in a key granulator for 3 minutes at a stir rate of 240 r.p.m. and an impeller rate of 3000 r.p.m. Purified water (57 ml) was added at a rate of approximately 4ml/minute for 13.5 minutes while the key granulator was set at a stir rate of 240 r.p.m. and the impeller rate was set at 1500 r.p.m. The mixture was stirred for a further 1 minute, and the resulting granules dried in an air oven at 50°C for 3 hours.
A solution of paroxetine hydrochloride hemihydrate (2.0 g) in ethanol (100 ml) was added to the granules prepared above (50 g) and the slurry dried under vacuum at 50°C.
Example 5
Preparation of tablet pre-mix containing paroxetine hydrochloride. A solution of paroxetine hydrochloride hemihydrate (2.0 g) in ethanol (150 ml) was added to celite (50 g), the mixture stirred and the slurry dried under vacuum at 50°C to afford a free moving powdery solid, suitable for use as a component of a tablet or capsule formulation.
Example 6
Preparation of tablet pre-mix containing paroxetine hydrochloride.
A stirred mixture of N-phenoxycarbonyl paroxetine ( 50.0 g), potassium hydroxide (45.0 g) and toluene ( 750 ml) was heated to reflux under a nitrogen atmosphere for 3 hours. After allowing the mixture to cool to room temperature, distilled water (500 ml) was added and the mixture stirred for 30 minutes. The organic layer was separated, dried over magnesium sulphate and filtered.
An aliquot of this solution of paroxetine free amine in toluene [ 0.048 g/ml] ( 21.0 ml) was diluted with a further 30 ml of toluene and heated to 60°C. Concentrated hydrochloric acid (0.34 ml) was added and the mixture stirred for 10 minutes.
Tablet granules ( 25. Og ), prepared as in Example 4, were added and the mixture stirred at 60°C for 5 minutes. Solvent was removed under reduced pressure at
70°C to afford a mobile powdery solid (26. Og).
Example 7
Preparation of tablet pre-mix containing paroxetine hydrochloride.
Concentrated hydrochloric acid (0.34ml) was added to a stirred solution of paroxetine acetate (1.18g) in toluene (50ml) at 60°C and the mixture stirred for 10 minutes. Tablet granules ( 25. Og ), prepared as in Example 4, were added and the mixture stirred at 60°C for 5 minutes. Solvent was removed under reduced pressure at 70°C to afford a free flowing powdery solid (26.0g).

Claims

1. Paroxetine or a pharmaceutically acceptable derivative thereof adsorbed on or absorbed by a solid carrier.
2. A pharmaceutical composition comprising paroxetine or a pharmaceutically acceptable derivative thereof adsorbed on or absorbed by a solid carrier.
3. Use of paroxetine or a pharmaceutically acceptable derivative thereof adsorbed on or absorbed by a solid carrier to manufacture a medicament for the treatment of depression.
4. A method of treating depression which comprises administering an effective amount of paroxetine or a pharmaceutically acceptable derivative thereof adsorbed on or absorbed by a solid carrier to a person suffering from depression.
5. A composition of matter, use or method according to any preceding claim wherein the paroxetine is in the form of its free base.
6. A process for the preparation of a composition of matter according to claim 1 , 2 or 5, which process comprises combining a solution of paroxetine or a pharmaceutically acceptable derivative thereof with the adsorbent or absorbent solid carrier material and evaporating the solvent.
7. A process according to claim 6, wherein the carrier material is suspended in the solvent prior to evaporation of the solvent.
8. A process according to claim 6, wherein the carrier material is dissolved in the solvent prior to evaporation of the solvent.
9. A process according to any one of claims 6 or 8, wherein the evaporation of the solvent is carried out by spray drying.
PCT/GB1999/000922 1998-03-24 1999-03-24 Paroxetine compositions WO1999048499A1 (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
PL99343095A PL343095A1 (en) 1998-03-24 1999-03-24 Paroxetine compositions
JP2000537547A JP2002507569A (en) 1998-03-24 1999-03-24 Paroxetine composition
CA002324612A CA2324612A1 (en) 1998-03-24 1999-03-24 Paroxetine compositions
NZ506893A NZ506893A (en) 1998-03-24 1999-03-24 Paroxetine compositions adsorbed or absorbed by a solid carrier
KR1020007010550A KR20010042145A (en) 1998-03-24 1999-03-24 Paroxetine Compositions
IL13847899A IL138478A0 (en) 1998-03-24 1999-03-24 Paroxetine compositions
APAP/P/2000/001914A AP2000001914A0 (en) 1998-03-24 1999-03-24 Paroxetine compositions.
EA200000977A EA003393B1 (en) 1998-03-24 1999-03-24 Paroxetine compositions
BR9908991-2A BR9908991A (en) 1998-03-24 1999-03-24 Compositions of paroxetine
AU30451/99A AU754765B2 (en) 1998-03-24 1999-03-24 Paroxetine compositions
EP99911940A EP1063993A1 (en) 1998-03-24 1999-03-24 Paroxetine compositions
SK1410-2000A SK14102000A3 (en) 1998-03-24 1999-03-24 Paroxetine compositions
NO20004740A NO313404B1 (en) 1998-03-24 2000-09-22 A pharmaceutical composition comprising paroxetine, a process for the preparation of the composition, and its use
BG104865A BG104865A (en) 1998-03-24 2000-10-16 Paroxetinne-containing compositions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9806312.6 1998-03-24
GBGB9806312.6A GB9806312D0 (en) 1998-03-24 1998-03-24 Novel formulations

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US09646622 A-371-Of-International 2000-11-28
US10/134,917 Continuation US6699882B2 (en) 1998-03-24 2002-04-29 Paroxetine compositions

Publications (1)

Publication Number Publication Date
WO1999048499A1 true WO1999048499A1 (en) 1999-09-30

Family

ID=10829181

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1999/000922 WO1999048499A1 (en) 1998-03-24 1999-03-24 Paroxetine compositions

Country Status (20)

Country Link
EP (1) EP1063993A1 (en)
JP (1) JP2002507569A (en)
CN (1) CN1125639C (en)
AP (1) AP2000001914A0 (en)
AU (1) AU754765B2 (en)
BG (1) BG104865A (en)
BR (1) BR9908991A (en)
CA (1) CA2324612A1 (en)
EA (1) EA003393B1 (en)
GB (1) GB9806312D0 (en)
HU (1) HUP0101326A3 (en)
ID (1) ID26485A (en)
IL (1) IL138478A0 (en)
NO (1) NO313404B1 (en)
NZ (1) NZ506893A (en)
PL (1) PL343095A1 (en)
SK (1) SK14102000A3 (en)
TR (1) TR200002750T2 (en)
WO (1) WO1999048499A1 (en)
ZA (1) ZA200005697B (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000078288A2 (en) * 1999-06-22 2000-12-28 Smithkline Beecham P.L.C. Novel process for paroxetine compositions
DK200100341A (en) * 2001-03-02 2002-09-03 Gea Farmaceutisk Fabrik As Process for the preparation of pharmaceutical tablets containing paroxetine hydrochloride anhydrate
US8062664B2 (en) 2003-11-12 2011-11-22 Abbott Laboratories Process for preparing formulations of lipid-regulating drugs

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2531097C (en) * 2003-07-02 2012-10-09 Abbott Laboratories Process for preparing formulations of lipid-regulating drugs
HU1000278D0 (en) * 2010-05-28 2010-07-28 Egis Gyogyszergyar Nyilvanosan Novel pharmaceutical use uf silicic acid
CN103961333B (en) * 2014-05-07 2020-02-21 浙江华海药业股份有限公司 Paroxetine mesylate capsule and preparation method thereof
CN104027306A (en) * 2014-06-25 2014-09-10 万特制药(海南)有限公司 Paroxetine oral suspension and preparation method thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0223403A2 (en) * 1985-10-25 1987-05-27 Beecham Group Plc Piperidine derivative, its preparation, and its use as medicament
DE19603797A1 (en) * 1995-02-06 1996-08-14 Smithkline Beecham Plc New forms of paroxetine hydrochloride

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1422263A (en) * 1973-01-30 1976-01-21 Ferrosan As 4-phenyl-piperidine compounds
CA2206592A1 (en) * 1996-05-30 1997-11-30 Shu-Zhong Wang Method of producing amorphous paroxetine hydrochloride

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0223403A2 (en) * 1985-10-25 1987-05-27 Beecham Group Plc Piperidine derivative, its preparation, and its use as medicament
DE19603797A1 (en) * 1995-02-06 1996-08-14 Smithkline Beecham Plc New forms of paroxetine hydrochloride
WO1996024595A1 (en) * 1995-02-06 1996-08-15 Smithkline Beecham Plc New forms of paroxetin hydrochloride

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000078288A2 (en) * 1999-06-22 2000-12-28 Smithkline Beecham P.L.C. Novel process for paroxetine compositions
WO2000078288A3 (en) * 1999-06-22 2001-02-15 Smithkline Beecham Plc Novel process for paroxetine compositions
DK200100341A (en) * 2001-03-02 2002-09-03 Gea Farmaceutisk Fabrik As Process for the preparation of pharmaceutical tablets containing paroxetine hydrochloride anhydrate
WO2002069969A1 (en) * 2001-03-02 2002-09-12 A/S Gea Farmaceutisk Fabrik A process for the manufacture of pharmaceutical tablets containing paroxetine hydrochloride anhydrate
US8062664B2 (en) 2003-11-12 2011-11-22 Abbott Laboratories Process for preparing formulations of lipid-regulating drugs

Also Published As

Publication number Publication date
EA200000977A1 (en) 2001-02-26
CA2324612A1 (en) 1999-09-30
SK14102000A3 (en) 2001-03-12
NO20004740D0 (en) 2000-09-22
NO20004740L (en) 2000-10-03
JP2002507569A (en) 2002-03-12
EA003393B1 (en) 2003-04-24
CN1294512A (en) 2001-05-09
CN1125639C (en) 2003-10-29
PL343095A1 (en) 2001-07-30
ID26485A (en) 2001-01-11
BG104865A (en) 2001-05-31
NZ506893A (en) 2003-06-30
TR200002750T2 (en) 2000-12-21
GB9806312D0 (en) 1998-05-20
AU754765B2 (en) 2002-11-21
HUP0101326A3 (en) 2002-06-28
BR9908991A (en) 2000-12-12
AP2000001914A0 (en) 2000-09-30
IL138478A0 (en) 2001-10-31
EP1063993A1 (en) 2001-01-03
ZA200005697B (en) 2001-10-02
HUP0101326A2 (en) 2002-05-29
AU3045199A (en) 1999-10-18
NO313404B1 (en) 2002-09-30

Similar Documents

Publication Publication Date Title
RU2349306C2 (en) Medicines containing vardenafil hydrochloride trihydrate
KR20010013543A (en) Pharmaceutical Composition For Combination Of Piperidinoalkanol-Decongestant
JP2002503248A (en) 4-phenylpiperidine compound
JP2005501074A (en) Paroxetine / glycyrrhizinate
AU754765B2 (en) Paroxetine compositions
WO2002017921A2 (en) Paroxetine compositions and processes for making the same
US6699882B2 (en) Paroxetine compositions
US6680334B2 (en) Crystalline material
JP2001517700A (en) Amorphous paroxetine composition
AU2003200534B2 (en) Paroxetine compositions
EP1963306A2 (en) Esomeprazole arginine
MXPA00009340A (en) Paroxetine compositions
MXPA02000033A (en) Polymorphs of crystalline (2-benzhydryl-1-azabicyclo[2,2, 2]oct-3-yl)-(5-isopropyl-2-methoxybenzyl)-ammoniumchloride as nk-1 receptor antagonists.
WO2001058449A1 (en) Water dispersible formulation of paroxetine
KR20010042145A (en) Paroxetine Compositions
KR100896563B1 (en) Pharmaceutical Composition Comprising Condensed Indole Compound
EP2943454B1 (en) Tapentadol maleate and crystalline forms thereof
CZ20003489A3 (en) Paroxetine compositions
EP1287826A1 (en) A crystalline form of the free base of Amlodipine
SK15912000A3 (en) Paroxetine ascorbate
CN103860473A (en) Medicinal composition of duloxetine
US20020028942A1 (en) Novel process and compound
WO2001012623A1 (en) Process for the preparation of paroxetine hydrochloride
WO2001025201A1 (en) Process for the preparation of paroxetin intermediate
WO2001017966A1 (en) Process for the preparation of 1-methyl-3-carbomethoxy-4-(4'-fluorophenyl)-piperidine

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 99804347.8

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 506893

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 30451/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 138478

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 1999911940

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2324612

Country of ref document: CA

Ref document number: 2324612

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 14102000

Country of ref document: SK

Ref document number: PV2000-3489

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: PA/a/2000/009340

Country of ref document: MX

Ref document number: 2000/02750

Country of ref document: TR

WWE Wipo information: entry into national phase

Ref document number: 1020007010550

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2000/05697

Country of ref document: ZA

Ref document number: 200005697

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 200000977

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 09646622

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1999911940

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV2000-3489

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1020007010550

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1020007010550

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1999911940

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: PV2000-3489

Country of ref document: CZ